| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 08/30/2001 | WO2001062092A1 Formulations and methods for using the same to elicit an immune response |
| 08/30/2001 | WO2001024842A3 Hybrid matrices and hybrid matrix mixtures |
| 08/30/2001 | WO2001014408A3 Method for coupling, in solution, a peptide with at least another compound and uses thereof |
| 08/30/2001 | WO2001009350A3 Genetically engineered bleb vaccine |
| 08/30/2001 | WO2001009187A3 Human monoclonal antibodies to her2/neu |
| 08/30/2001 | WO2001008702A3 Immunotherapy in hiv infected persons using vaccines after multi-drug treatment |
| 08/30/2001 | WO2000041719A9 Methods of using a neurotrophin and its analogues for the treatment of gastrointestinal hypomotility disorders |
| 08/30/2001 | WO2000040614A9 Characterization of the soc/crac calcium channel protein family |
| 08/30/2001 | WO2000040597A9 Method and composition for angiogenesis inhibition |
| 08/30/2001 | US20010018415 Treating cholinergic controlled secretions including excessive sweating, lacrimation and mucus secretion by administering Botulinum toxin type A |
| 08/30/2001 | US20010018210 Contacting cells with dipeptidyl peptidase inhibitor immobilized by attachment to container or magetic particle or as part of heteroconjugate with antigenic peptide |
| 08/30/2001 | US20010018058 Isolated polypeptide comprising an immunogenic portion of a breast protein comprising an amino acid sequence encoded by a polynucleotide |
| 08/30/2001 | US20010018056 Administering intranasally an antigen which is a non-toxic double mutant form of pertussis toxin inducing an immune response |
| 08/30/2001 | US20010018055 Safe, effectives vaccines for cattle, sheep and goats |
| 08/30/2001 | US20010018054 Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis |
| 08/30/2001 | US20010018053 Methods for treating disease states comprising administration of low levels of antibodies |
| 08/30/2001 | US20010018041 Lymphomas, leukemia |
| 08/30/2001 | CA2683009A1 Use of il-18 inhibitors |
| 08/30/2001 | CA2401219A1 Vertebrate globin |
| 08/30/2001 | CA2401070A1 Compositions and methods for diagnosis and therapy of malignant mesothelioma |
| 08/30/2001 | CA2401031A1 Tlp peptides and dna sequences coding the same |
| 08/30/2001 | CA2400874A1 Membrane estrogen receptor-directed therapy in breast cancer |
| 08/30/2001 | CA2400842A1 Novel compounds |
| 08/30/2001 | CA2400838A1 Novel method for down-regulation of amyloid |
| 08/30/2001 | CA2400661A1 Novel antibody with specificity for colon cancer |
| 08/30/2001 | CA2400636A1 Hybrid cell vaccines |
| 08/30/2001 | CA2400622A1 Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis |
| 08/30/2001 | CA2400606A1 New phosphodiesterase type 7b |
| 08/30/2001 | CA2400215A1 Hla binding peptides and their uses |
| 08/30/2001 | CA2399999A1 Use of breast cancer associated membrane proteins (bcmp) for treatment, prophylaxis and diagnosis of breast cancer |
| 08/30/2001 | CA2399298A1 Use of il-18 inhibitors |
| 08/30/2001 | CA2399255A1 Caspase activated prodrugs therapy |
| 08/30/2001 | CA2394088A1 Method for transdermal or intradermal delivery of molecules |
| 08/29/2001 | EP1127893A2 Compositions and methods for the treatment and diagnosis of breast cancer |
| 08/29/2001 | EP1127576A1 Uses of NM23-polypeptides in skin and intestinal disorders |
| 08/29/2001 | EP1127260A1 Immunotherapy of b cell involvement in progression of solid, nonlymphoid tumors |
| 08/29/2001 | EP1127170A1 Human pan-hcv human monoclonal antibodies |
| 08/29/2001 | EP1127137A1 Lps with reduced toxicity from genetically modified gram negative bacteria |
| 08/29/2001 | EP1127134A1 Rotavirus subunit vaccine |
| 08/29/2001 | EP1127133A2 Polypeptide mediating cell permeability |
| 08/29/2001 | EP1127132A1 Peptides useful for reducing symptoms of toxic shock syndrome and septic shock |
| 08/29/2001 | EP1127123A2 Cell surface glycoproteins |
| 08/29/2001 | EP1127119A1 Compounds and methods for modulating claudin-mediated functions |
| 08/29/2001 | EP1127110A1 Modified exosomes and uses |
| 08/29/2001 | EP1127069A2 Biological materials and methods useful in the diagnosis and treatment of prion diseases |
| 08/29/2001 | EP1127067A2 Inhibition of transglutaminase-mediated microbial interaction with a mammalian host |
| 08/29/2001 | EP1127065A2 $i(chlamydia) antigens and corresponding dna fragments and uses thereof |
| 08/29/2001 | EP1127064A1 Novel amino acid sequences, dna encoding the amino acid sequences, antibodies directed against such sequences and the different uses thereof |
| 08/29/2001 | EP1126878A1 Heparanase activity neutralizing anti-heparanase monoclonal antibody |
| 08/29/2001 | EP1126877A1 Method of diagnosing, monitoring, staging, imaging and treating prostate cancer |
| 08/29/2001 | EP1126876A2 Adjuvant systems and vaccines |
| 08/29/2001 | EP1126875A2 Pharmaceutically active composition and dispensing device |
| 08/29/2001 | EP1126874A2 Multicomponent meningococcal vaccine |
| 08/29/2001 | EP1126873A1 Method for enhancing proliferation of inner ear hair cells using ligands for her2 and/or her3 receptors |
| 08/29/2001 | EP1126872A1 CANCER IMMUNOTHERAPHY AND DIAGNOSIS USING UNIVERSAL TUMOR ASSOCIATED ANTIGENS, INCLUDING hTERT |
| 08/29/2001 | EP1126866A2 A method for inhibition of phospholamban activity for the treatment of cardiac disease and heart failure |
| 08/29/2001 | EP1126864A1 Binding moieties for human parvovirus b19 |
| 08/29/2001 | EP1126857A1 A method of activating t cells and agents useful for same |
| 08/29/2001 | EP1126842A2 Inhibition of the formation of vascular hyperpermeability |
| 08/29/2001 | EP0941118B1 Pharmaceutical antigen-antibody preparation |
| 08/29/2001 | EP0751709B1 Use of bcl-2 for the manufacture of medicaments for the therapeutic treatment and prevention of diseases |
| 08/29/2001 | CN1310759A Therapeutic and diagnostic domain 1 & beta 2GP1 polypeptides and methods of using same |
| 08/29/2001 | CN1310628A Method of raising animals for meat production |
| 08/29/2001 | CN1310625A Use of alpha1 & beta1 integrin receptor inhibitors and TGF-beta1 inhibitors in the treatment of kidney disease |
| 08/29/2001 | CN1310618A Inhibition of binding of Hox and homeodomain containing proteins and uses thereof |
| 08/29/2001 | CN1310023A Specific immunological inhibitor |
| 08/29/2001 | CN1070198C Isolated nucleic acid molecule of coded tumor rejection antigen precursor DAGE and its application |
| 08/29/2001 | CN1070078C Process for producing vaccine of foot-and-mouth disease |
| 08/28/2001 | US6281345 A nucleic acid isolated from dirofilaria immitis; therapy for animals with helminth infections |
| 08/28/2001 | US6281336 Process for producing immunoglobulins for intravenous administration and other immunoglobulin products |
| 08/28/2001 | US6281236 Containing allantoin and an emulsifier has improved stability coming from the adjustment of the ph to a range of 4.5 to 5.8. |
| 08/28/2001 | US6281012 Preventing graft versus host disease |
| 08/28/2001 | US6281000 Dna fragment cloning into genome of recombinant adenoviral plasmid vector; human gene therapy |
| 08/28/2001 | US6280974 Nucleotide sequence coding viral protein; for use as diagnostic tool in detection of viral diseases |
| 08/28/2001 | US6280973 Mammalian methadone-specific opioid receptor gene and uses |
| 08/28/2001 | US6280971 Polynucleotide associated with detection of staphylococcus; for use in screening bactericides |
| 08/28/2001 | US6280957 Preventing graft rejection in humans; administer human a modulator of ligand activity, insert hematopoietic stem cells and graft into human, monitor response to grafts |
| 08/28/2001 | US6280743 Use of mCRP to enhance immune responses |
| 08/28/2001 | US6280742 Methods and materials for the treatment of prostatic carcinoma |
| 08/28/2001 | US6280741 Administering to horse effective amount of haemophilus somnus vaccine containing killed bacterin of haemophilus to treat for navicular disease |
| 08/28/2001 | US6280740 Formulations of recombinant papillomavirus vaccines |
| 08/28/2001 | US6280738 Non-IgA Fc binding forms of the group B streptococcal β antigens |
| 08/28/2001 | US6280735 Polypeptides of riboflavin specific deaminase family |
| 08/28/2001 | US6280734 Simian-human HAV having a chimeric 2C protein |
| 08/28/2001 | US6280730 Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin |
| 08/28/2001 | CA2333930A1 Dna sequence encoding the specific and antigenic outer membrane protein of s amonella typhi |
| 08/28/2001 | CA2203443C Hepatitis c virus asialoglycoproteins |
| 08/28/2001 | CA2190591C Microparticle delivery system |
| 08/28/2001 | CA2111845C Monoclonal antibodies specific for marrow-derived mesenchymal cells |
| 08/28/2001 | CA2079902C Antibody conjugates for treatment of neoplastic disease |
| 08/28/2001 | CA1341287C Polypeptides derived from human papillomavirus, antibodies to said polypeptide and detection of human papillomavirus latent proteins |
| 08/23/2001 | WO2001061356A1 Her-2 binding antagonists |
| 08/23/2001 | WO2001061055A2 Methods for diagnosing, monitoring, staging, imaging and treating lung cancer via lung cancer specific genes |
| 08/23/2001 | WO2001061017A2 Modified cytokines for use in cancer therapy |
| 08/23/2001 | WO2001061013A1 Haemophilus influenza outer membrane protein and use thereof in vaccination |
| 08/23/2001 | WO2001061009A2 Polypeptides and nucleic acids encoding same |
| 08/23/2001 | WO2001061008A2 Polypeptides and nucleic acids encoding same |
| 08/23/2001 | WO2001061007A2 Fibroblast growth factor-23 molecules and uses thereof |
| 08/23/2001 | WO2001060975A2 Gene disruption methodologies in fungi for drug target discovery |
| 08/23/2001 | WO2001060857A2 Compositions useful for regulating parkin gene activity |